Matching articles for "Dalteparin"
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Comparison Table: Some Parenteral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
...
View the Comparison Table: Some Parenteral Anticoagulants for VTE
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US guidelines
for treatment of VTE were published in 2016.
Comparison Table: Some Parenteral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
...
View the Comparison Table: Some Parenteral Anticoagulants for VTE
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 27, 2014; (Issue 1454)
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 1, 2011; (Issue 110)
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but...
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but anticoagulants
are also effective, and their effects can add to those of
antiplatelet drugs. Venous thrombi are composed
mainly of fibrin and trapped red blood cells, with relatively
few platelets. Anticoagulants are the agents of
choice for prevention and treatment of venous thromboembolism
and for prevention of cardioembolic
events in patients with atrial fibrillation.
Antiplatelet and Anticoagulant Drugs
The Medical Letter on Drugs and Therapeutics • May 1, 2008; (Issue 69)
Arterial and venous thrombosis are major causes of morbidity and mortality. Arterial thrombi consist of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice...
Arterial and venous thrombosis are major causes of morbidity and mortality. Arterial thrombi consist of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but anticoagulants are also effective, and their effects can add to those of antiplatelet drugs. Venous thrombi are composed mainly of fibrin and trapped red blood cells, with relatively few platelets. Anticoagulants are the agents of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Fondaparinux (Arixtra), A New Anticoagulant
The Medical Letter on Drugs and Therapeutics • May 13, 2002; (Issue 1130)
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip...
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
The Medical Letter on Drugs and Therapeutics • February 19, 2001; (Issue 1098)
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein...
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.
Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
The Medical Letter on Drugs and Therapeutics • October 10, 1997; (Issue 1011)
Ardeparin sodium (Normiflo - Wyeth-Ayerst), a low-molecular-weight heparin, and danaparoid sodium (Orgaran - Organon), a heparinoid, have been approved by the FDA for prevention of deep vein thrombosis....
Ardeparin sodium (Normiflo - Wyeth-Ayerst), a low-molecular-weight heparin, and danaparoid sodium (Orgaran - Organon), a heparinoid, have been approved by the FDA for prevention of deep vein thrombosis. Without anticoagulation, deep vein thrombosis occurs in up to 30% of patients after abdominal surgery, and in 40% to 70% of patients after major orthopedic operations on the lower limbs. Danaparoid sodium is approved in the USA only for use in hip replacement. Ardeparin is approved here only for use in knee replacement.
Dalteparin - Another Low-Molecular-Weight Heparin
The Medical Letter on Drugs and Therapeutics • December 8, 1995; (Issue 963)
Dalteparin (Fragmin - Pharmacia), the second low-molecular-weight heparin to be marketed in the USA, is now available for prevention of deep vein thrombosis in high-risk patients after abdominal surgery....
Dalteparin (Fragmin - Pharmacia), the second low-molecular-weight heparin to be marketed in the USA, is now available for prevention of deep vein thrombosis in high-risk patients after abdominal surgery. Enoxaparin (Lovenox -Rh ne-Poulenc Rorer) was approved in 1993 for prevention of deep vein thrombosis after hip replacement (Medical Letter, 35:75, 1993) and later approved for use in knee replacement. Five other low-molecular-weight heparins and one heparinoid are under investigation in the USA (MJ Cziraky and SA Spinler, Clin Pharm, 12:892, 1993).